雷珠单抗与阿柏西普治疗新生血管性年龄相关性黄斑变性中视网膜厚度波动的影响(SALT):多中心、随机、IV期试验的12个月结果
这项前瞻性12个月IV期随机多中心研究比较了雷珠单抗按需治疗与阿柏西普每两月治疗新生血管性年龄相关性黄斑变性的中央子区域视网膜厚度波动。两组间视网膜厚度波动数值差异未达统计学显著,预设的视网膜稳定性分析(校正基线CSRT后)显示雷珠单抗组波动小于阿柏西普组,但第3至6个月的平均波动幅度与第12个月最佳矫正视力无相关性。
要点
- 雷珠单抗按需组与阿柏西普每两月组CSRT波动LS均值差为-4.12(95%CI -10.22至1.98)µm,p=0.1850,未达统计学显著。
- 预设的视网膜稳定性分析校正基线CSRT后,LS均值差为-6.53(95%CI -12.47至-0.58)µm,支持雷珠单抗(p=0.0315)。
- 第3至6个月CSRT平均波动幅度与第12个月BCVA无相关性(Pearson r=-0.0888)。
核心结论
- 第3至6个月两种治疗方案的视网膜厚度波动存在数值差异,但第3至6个月的平均波动幅度与第12个月功能结局无相关性。
研究设计与样本
- 前瞻性、12个月、IV期、随机、多中心研究,比较新生血管性年龄相关性黄斑变性患者接受雷珠单抗按需治疗与阿柏西普每两月治疗的中央子区域视网膜厚度波动。
- 雷珠单抗根据最佳矫正视力和/或谱域光学相干断层扫描检测到的疾病活动给药;阿柏西普在最初三次每月访视后改为每两月治疗。
- 在第3至6个月评估CSRT稳定性,比较组间差异并与第12个月功能结局进行相关性分析。
主要发现
- CSRT波动LS均值(95%CI):雷珠单抗组25.16(20.09至30.24)µm vs 阿柏西普组29.28(24.14至34.43)µm,LS均值差-4.12(-10.22至1.98)µm,p=0.1850。
- 预设视网膜稳定性分析(校正基线CSRT)LS均值(95%CI):雷珠单抗组23.53(18.58至28.49)µm vs 阿柏西普组30.06(25.04至35.07)µm,LS均值差-6.53(-12.47至-0.58)µm,p=0.0315,支持雷珠单抗。
- Pearson相关系数显示第3至6个月CSRT平均波动幅度与第12个月BCVA无相关性(r=-0.0888)。
- 不良事件发生率低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: To compare fluctuations of central subfield retinal thickness (CSRT) in patients with neovascular age-related macular degeneration undergoing ranibizumab pro re nata versus aflibercept bimonthly treatment in a prospective 12 month, phase IV, randomised, multicentre study. METHODS: Ranibizumab was administered according to best-corrected visual acuity (BCVA) and/or disease activity detected on spectral domain optical coherence tomography. Aflibercept was administered at three initial monthly visits followed by bimonthly treatment. CSRT stability was evaluated between months 3 and 6. CSRT stability was compared between groups and correlated with functional outcomes at month 12. RESULTS: Fluctuations of CSRT showed a least-squares (LS) mean (95% CI) difference of -4.12 (-10.22 to 1.98) µm between ranibizumab (25.16 (20.09 to 30.24) µm) and aflibercept groups (29.28 (24.14 to 34.43) µm) (p=0.1850). A predefined analysis of retinal stability, adjusted for baseline CSRT, showed a LS mean (95% CI) difference of -6.53 (-12.47 to -0.58 µm) in favour of ranibizumab (23.53 (18.58 to 28.49) µm) versus aflibercept (30.06 (25.04 to 35.07) µm) (p=0.0315). Pearson's correlation coefficient demonstrated no correlation between the mean amplitude of CSRT fluctuation between months 3 and 6, and BCVA at month 12 (r = -0.0888). Adverse event rates were low. CONCLUSIONS: Numerical differences in retinal thickness fluctuations between months 3 and 6 were detected between treatment regimens. While the presence of fluctuations has previously been shown to have a negative impact on functional outcomes, our data showed no correlation between the mean amplitude of fluctuations and functional outcomes at month 12.
引用
- Agostini HT, Silva R, Holz FG, et al. Impact of retinal thickness fluctuations with ranibizumab versus aflibercept in neovascular age-related macular degeneration (SALT): 12-month results from a multicentre, randomised, phase IV trial. Br J Ophthalmol. 2025. PMID: 40707177. doi:10.1136/bjo-2024-326526
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。